CELL INTELLIGENCE · 肿瘤细胞治疗研究

Recent advancements in melanoma treatment have reinvigorated hope among patients, significantly shifting the therapeutic landscape. A significant advancement in patient outcomes has been realised by applying first-line treatment strategies that include Immune Checkpoint Inhibitors (ICIs) and targeted therapies. Ipilimumab combined with nivolumab has demonstrated superior outcomes, earning a median overall survival surpassing 70 months. This notable success signifies a pivotal shift in the management of advanced melanoma, reflecting effective therapeutic strategies that clinicians can leverage. The advent of new ICIs, such as relatlimab, introduces additional complexities in decision-making for first-line therapy. Understanding the nuances of various treatments will empower physicians to make informed decisions. Several important characteristics, including brain metastases, PD-L1 expression, BRAF mutation status, performance status, and any previous adjuvant treatments, influence the treatment of advanced melanoma. These factors influence the choice of therapy and the potential efficacy in individual cases, underscoring the need for personalised treatment approaches. This review also sheds light on rare melanoma subtypes, particularly uveal melanoma. The FDA approval of tebentafusp and lifileucel has demonstrated potential in extending the survival time of patients with metastatic uveal melanoma. This progress highlights the importance of innovative therapies tailored to unique cancer profiles. By providing recent insights into these evolving treatment options, this review is an invaluable resource for clinicians. It aims to facilitate informed treatment decisions and enhance understanding of the multifaceted challenges in effectively managing advanced melanoma. As new therapies emerge, continuous education and adaptability will be key to optimising patient outcomes.